

Longevity over the next decade: What will drive changes to assumptions over the next ten years?

15 March 2023 Andrew Devine Kara Scott



Hymans Robertson LLP® is a limited liability partnership registered in England and Wales with registered number OC310282. Authorised and regulated by the Financial Conduct Authority and licensed by the Institute and Faculty of Actuaries for a range of investment business activities.

Longevity over the next decade





Andrew Devine
Consultant
Andrew.devine@hymans.co.uk



Kara Scott
Associate Consultant
Kara.scott@hymans.co.uk

What we'll cover –

- 1 Setting the scene
- 2 Current situation: excess deaths
- 3 Longevity headwinds
- 4 Longevity tailwinds
- 5 Summary












Baseline mortality

- Assesses the level of mortality that has been experienced in the past.
- A relatively objective calculation, determined using historical data.
- Judgements may arise regarding the data period to use and how to deal with outlier data or extreme events


Future mortality improvements

- Quantifies how mortality rates will change in the future.
- A subjective calculation, requiring assumptions to be made
- Generally assessed using a mortality improvements model, such as the CMI model.




























Widespread usage of the CMI model






Slower trend expected in the coming decades



Outcome will depend on real world drivers



Longevity headwinds and tailwinds



Dementia / Alzheimer's

breakthrough

challenges



Al in healthcare

Universal flu

vaccine

mRNA cancer

vaccines

Social care

reforms

Diet incl.

Vegetarianism

Wearables to

monitor health

resistance


Obesity

trends

Current situation: excess deaths

Excess deaths in the UK

Cumulative excess deaths as % of average deaths over 2015 to 2019 (England & Wales)




High levels of excess deaths in second half of 2022



2022/23 Flu season






Higher number of hospital admissions for flu than for COVID-19 in December 2022



NHS waiting times






The Royal College of Emergency Medicine has estimated that delays in A&E are leading to 300-500 additional deaths per week



COVID-19

Weekly deaths and excess deaths involving COVID-19, England




Source: Office for National Statistics - Death registration data, England

COVID progressing from a pandemic to an endemic disease

COVID-19

Infection fatality ratio by age for COVID-19 and seasonal flu at March 2022 (log scale)




Source: Financial Times, March 10 2022

Severity of endemic COVID may be similar to flu at older ages



Dementia & Alzheimer's

Age-standardised mortality rates for leading causes of death (men)



Source: Office for National Statistics - Death registration data, England

Dementia and Alzheimer's an obstacle to future mortality improvements

Dementia & Alzheimer's





Alzheimer's / Success of experimental new drug hailed as 'historic moment'

Source: The Guardian 29/9/2022

Benefits of new treatments may be slow to emerge

Dementia & Alzheimer's




Alzheimer's / Success of experimental new drug hailed as 'historic moment'

Source: The Guardian 29/9/2022

Alzheimer's drug aducanumab not approved for use in EU

(§ 17 December 202


<



Source: The BBC 17/12/2022

Benefits of new treatments may be slow to emerge

NHS funding



Challenge to find additional sources of NHS funding







Recent cancer statistics








Average stage at diagnosis (England, 2019)



5-year survival rate (England, diagnosed in 2013-2017)



Sources: Number of deaths - <u>Cancer Research UK</u>. Note deaths for breast cancer for 2016 -2018. Average stage at diagnosis – Hymans Robertson analysis of National Disease Registration Service (<u>NDRS</u>) data, 5 year survival rates – <u>ONS</u>, Note average rate shown for men and women for lung and bowel cancer.

Huge potential for lung cancer mortality improvements

Lung cancer screening

Hundreds of people diagnosed with cancer early through life-saving NHS lung checks

NHS, April 2022



What is it?

Mobile trucks
Low dose CT scanning
Al solutions to read
images

Who is eligible?



ages 55 - 74

Estimated 1.5m invited by 2024/25

Does it work?

77% of cancers caught at either stage 1 or 2 (vs. < 33% in 2018)

Nationwide roll out could boost mortality improvements in cancer

Anti-ageing drugs: Metformin



Will This Diabetes Drug Slow Down Aging?


Healthline, 2022

As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked

STAT news, 2022

Diabetes Drug Metformin Shows Potential Benefit in Large COVID-19 Trial

Northwestern medicine, 2022




Anti-ageing drugs could have a material impact in the longer-term







Slower trend expected in the coming decades



Benefits of a driver-based perspective



Best estimate assumptions



Sense checking CMI projection



Stressed assumptions



Event risk calibration



Deriving allowance for COVID-19



Stress and scenario testing



Avoid herding of assumptions



Horizon scanning

Driver-based approach compliments extrapolative models



Thank you

The material and charts included herewith are provided as background information for illustration purposes only. This PowerPoint presentation is not a definitive analysis of the subjects covered and should not be regarded as a substitute for specific advice in relation to the matters addressed. It is not advice and should not be relied upon. This PowerPoint presentation contains confidential information belonging to Hymans Robertson LLP (HR) and should not be released or otherwise disclosed to any third party without prior consent from HR. HR accept no liability for errors or omissions or reliance upon any statement or opinion herein.

© Hymans Robertson LLP. All rights reserved.

